Vertex Pharmaceuticals reported a 3% revenue bump in Q1 2025, raking in $2.77 billion with swagger and science. Driven by a ...

Retail sentiment surrounding Vertex Pharmaceuticals Inc. (VRTX) surged on Monday, as message volume on Stocktwits spiked ...

Discover Vertex Pharmaceuticals' Q1 2025 earnings insights, with 3% revenue growth, key product launches like JOURNAVX & ALYFTREK, & raised ...

Vertex Pharmaceuticals (NASDAQ:VRTX) missed on the top and bottom lines in its Q1 financial results and also raised the low ...

Vertex shares fell in after-hours trading, as investors considered a stock trading near its all-time high with a longer wait ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Get his next trade alert for free, right here. Vertex Pharmaceuticals Inc VRTX is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in ...

announced today that it has filed a patent infringement lawsuit in the United Kingdom against Vertex Pharmaceuticals and its commercial manufacturing partners, Lonza and RoslinCT, regarding Vertex ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Kewalramani emigrated to the United States at the age of 11, and is now the first female CEO of a large, public U.S. biotechnology company Vertex Pharmaceuticals. "Under her leadership ...

The 'Leaders' list however does include Reshma Kewalramani this year, the Indian-Origin CEO of Vertex Pharmaceuticals. She immigrated from India at age 11 and went on to become the first woman CEO ...